Cerebro-renal interaction and stroke.
cerebrorenal interactions
chronic kidney disease
endothelial dysfunction
stroke
uremic toxins
Journal
The European journal of neuroscience
ISSN: 1460-9568
Titre abrégé: Eur J Neurosci
Pays: France
ID NLM: 8918110
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
30
06
2020
revised:
20
08
2020
accepted:
09
09
2020
pubmed:
27
9
2020
medline:
29
6
2021
entrez:
26
9
2020
Statut:
ppublish
Résumé
Stroke is an event causing a disturbance in cerebral function leading to death and disability worldwide. Both acute kidney injury and chronic kidney disease (CKD) are associated with an increased risk of stroke and cerebrovascular events. The underlying mechanistic approach between impaired renal function and stroke is limitedly explored and has attracted researchers to learn more for developing therapeutic intervention. Common risk factors such as hypertension, hyperphosphatemia, atrial fibrillation, arteriosclerosis, hyperhomocysteinemia, blood-brain barrier disruption, inflammation, etc. are observed in the general population, but are high in renal failure patients. Also, risk factors like bone mineral metabolism, uremic toxins, and anemia, along with the process of dialysis in CKD patients, eventually increases the risk of stroke. Therefore, early detection of risks associated with stroke in CKD is imperative, which may decrease the mortality associated with it. This review highlights mechanisms by which kidney dysfunction can lead to cerebrovascular events and increase the risk of stroke in renal impairment.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1299Informations de copyright
© 2020 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
Références
Abramson, J. L., Jurkovitz, C. T., Vaccarino, V., Weintraub, W. S., & Mcclellan, W. (2003). Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney International, 64, 610-615. https://doi.org/10.1046/j.1523-1755.2003.00109.x
Aggarwal, A., Aggarwal, P., Khatak, M., & Khatak, S. (2010). Cerebral ischemic stroke: Sequels of cascade. International Journal of Pharmacy and Biological Sciences, 1, 1-24.
Aguilar, M., O'Meara, E., Seliger, S., Longstreth, W., Hart, R., Pergola, P., Shlipak, M., Katz, R. Sarnak, M. J., & Rifkin, D. E. (2010). Albuminuria and the risk of incident stroke and stroke types in older adults. Neurology, 75, 1343-1350. https://doi.org/10.1212/WNL.0b013e3181f73638
Akoudad, S., Portegies, M. L., Koudstaal, P. J., Hofman, A., van der Lugt, A., Ikram, M. A., & Vernooij, M. W. (2015). Cerebral microbleeds are associated with an increased risk of stroke: The Rotterdam Study. Circulation, 132, 509-516. https://doi.org/10.1161/CIRCULATIONAHA.115.016261
Arnold, R., Issar, T., Krishnan, A. V., & Pussell, B. A. (2016). Neurological complications in chronic kidney disease. JRSM cardiovascular disease, 5, 2048004016677687.
Arnold, J., Sims, D., & Ferro, C. J. (2015). Modulation of stroke risk in chronic kidney disease. Clinical Kidney Journal, 9, 29-38. https://doi.org/10.1093/ckj/sfv136
Assem, M., Lando, M., Grissi, M., Kamel, S., Massy, Z., Chillon, J.-M., & Hénaut, L. (2018). The impact of uremic toxins on cerebrovascular and cognitive disorders. Toxins, 10, 303. https://doi.org/10.3390/toxins10070303
Aursulesei, V., & Costache, I. I. (2019). Anticoagulation in chronic kidney disease: From guidelines to clinical practice. Clinical Cardiology, 42, 774-782. https://doi.org/10.1002/clc.23196
Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 23, 1631-1634. https://doi.org/10.1681/ASN.2011111078
Bennett, C. L., Becker, P. S., Kraut, E. H., Samaras, A. T., & West, D. P. (2009) Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Vol. 22, Seminars in dialysis. Wiley Online Library, City. pp. 1-4.
Binder, C., Lauritzen, T., Faber, O., & Pramming, S. (1984). Insulin pharmacokinetics. Diabetes Care, 7, 188-199. https://doi.org/10.2337/diacare.7.2.188
Boldyrev, A., Bryushkova, E., Mashkina, A., & Vladychenskaya, E. (2013). Why is homocysteine toxic for the nervous and immune systems? Current Aging Science, 6, 29-36.
Boriani, G., Savelieva, I., Dan, G.-A., Deharo, J. C., Ferro, C., Israel, C. W., Lane, D. A., La Manna, G., Morton, J., Mitjans, A. M., Vos, M. A., Turakhia, M. P., Lip, G. Y. H., Gorenek, B., Takahashi, Y., Lau, Dennis, Chung, M., Nielsen, J. C., Fauchier, L., … Brignole, M. (2015). Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: Clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Ep Europace, 17, 1169-1196. https://doi.org/10.1093/europace/euv202
Bramlett, H. M., & Dietrich, W. D. (2004). Pathophysiology of cerebral ischemia and brain trauma: Similarities and differences. Journal of Cerebral Blood Flow & Metabolism, 24, 133-150. https://doi.org/10.1097/01.WCB.0000111614.19196.04
Brooks, J. M., Chapman, C. G., Suneja, M., Schroeder, M. C., Fravel, M. A., Schneider, K. M., Wilwert, J., Li, Y. J., Chrischilles, E. A., Brenton, D. W., Brenton, M., & Robinson, J. (2018). Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for geriatric ischemic stroke patients: Are the rates right? Journal of the American Heart Association, 7(11), e009137. https://doi.org/10.1161/JAHA.118.009137
Brouns, R., & De Deyn, P. (2004). Neurological complications in renal failure: A review. Clinical Neurology and Neurosurgery, 107, 1-16. https://doi.org/10.1016/j.clineuro.2004.07.012
Bülow, R. D., & Boor, P. (2019). Extracellular matrix in kidney fibrosis: More than just a scaffold. Journal of Histochemistry & Cytochemistry, 67(9), 643-661. 0022155419849388. https://doi.org/10.1369/0022155419849388
Burn, D., & Bates, D. (1998). Neurology and the kidney. Journal of Neurology, Neurosurgery & Psychiatry, 65, 810-821. https://doi.org/10.1136/jnnp.65.6.810
Campbell, B. C., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019). Ischaemic stroke. Nature Reviews Disease Primers, 5(1), 1-22. https://doi.org/10.1038/s41572-019-0118-8
Cases, A., Escolar, G., Reverter, J. C., Ordinas, A., Lopez-Pedret, J., Revert, L., & Castillo, R. (1992). Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney International, 42, 668-672. https://doi.org/10.1038/ki.1992.333
Centers for Disease Control and Prevention. U.S. Department of Health & Human Services.
Chan, D. T., Dogra, G. K., Irish, A. B., Ooi, E. M., Barrett, P. H., Chan, D. C., & Watts, G. F. (2009). Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III. Journal of Lipid Research, 50, 2524-2531. https://doi.org/10.1194/jlr.P900003-JLR200
Chelluboina, B., & Vemuganti, R. (2019). Chronic kidney disease in the pathogenesis of acute ischemic stroke. Journal of Cerebral Blood Flow & Metabolism, 39(10), 1893-1905. https://doi.org/10.1177/0271678X19866733
Chen, S., Martens-Lobenhoffer, J., Weissenborn, K., Kielstein, J. T., Lichtinghagen, R., Deb, M., Li, N., Tryc, A. B., Goldbecker, A., Dong, Q., Bode-Böger, S. M., & Worthmann, H. (2012). Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. Journal of Neuroinflammation, 9, 251. https://doi.org/10.1186/1742-2094-9-251
Chue, C. D., Townend, J. N., Steeds, R. P., & Ferro, C. J. (2010). Republished paper: Arterial stiffness in chronic kidney disease: Causes and consequences. Postgraduate Medical Journal, 86, 560-566. https://doi.org/10.1136/pgmj.2009.184879rep
Chung, S., Jeong, H. S., Choi, D. E., Song, H.-J., Lim, Y. G., Ham, J. Y., Na, K. R., & Lee, K. W. (2016). The impact of hemodialysis and arteriovenous access flow on extracranial hemodynamic changes in end-stage renal disease patients. Journal of Korean Medical Science, 31, 1239-1245. https://doi.org/10.3346/jkms.2016.31.8.1239
Cohen, E., Margalit, I., Shochat, T., Goldberg, E., & Krause, I. (2019). Gender differences in homocysteine concentrations, a population-based cross-sectional study. Nutrition, Metabolism and Cardiovascular Diseases, 29, 9-14. https://doi.org/10.1016/j.numecd.2018.09.003
Collaboration, P. S. (2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903-1913.
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., & Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139-1151. https://doi.org/10.1056/NEJMoa0905561
Coyne, D. W. (2012). The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney International, 82, 235-241. https://doi.org/10.1038/ki.2012.76
Dad, T., & Weiner, D. E. (2015). Stroke and chronic kidney disease: Epidemiology, pathogenesis, and management across kidney disease stages. Vol. 35, Seminars in nephrology. Elsevier, City. pp. 311-322.
Dahal, K., Kunwar, S., Rijal, J., Schulman, P., & Lee, J. (2016). Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: A meta-analysis of observational studies. Chest, 149, 951-959. https://doi.org/10.1378/chest.15-1719
de Courten-Myers, G., Myers, R. E., & Schoolfield, L. (1988). Hyperglycemia enlarges infarct size in cerebrovascular occlusion in cats. Stroke, 19, 623-630. https://doi.org/10.1161/01.STR.19.5.623
De Deyn, P. P., D'hooge, R., Van Bogaert, P.-P. and Marescau, B. (2001). Endogenous guanidino compounds as uremic neurotoxins. Kidney International, 59, S77-S83.
De Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004). Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation, 110, 921-927. https://doi.org/10.1161/01.CIR.0000139860.33974.28
Delmez, J. A., & Slatopolsky, E. (1992). Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. American Journal of Kidney Diseases, 19, 303-317. https://doi.org/10.1016/S0272-6386(12)80446-X
Derdeyn, C. P. (2007). Mechanisms of ischemic stroke secondary to large artery atherosclerotic disease. Neuroimaging Clinics of North America, 17, 303-311. https://doi.org/10.1016/j.nic.2007.03.001
Dhondup, T., & Qian, Q. (2017). Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purification, 43, 179-188. https://doi.org/10.1159/000452725
Diao, M., Qu, Y., Liu, H., Ma, Y., & Lin, X. (2019). Effect of carbamylated erythropoietin on neuronal apoptosis in fetal rats during intrauterine hypoxic-ischemic encephalopathy. Biological Research, 52, 28. https://doi.org/10.1186/s40659-019-0234-7
Drechsler, C., Kalim, S., Wenger, J. B., Suntharalingam, P., Hod, T., Thadhani, R. I., Karumanchi, S. A., Wanner, C. & Berg, A. H. (2015). Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney International, 87, 1201-1208. https://doi.org/10.1038/ki.2014.429
Duni, A., Liakopoulos, V., Rapsomanikis, K.-P., & Dounousi, E. (2017). Chronic kidney disease and disproportionally increased cardiovascular damage: Does oxidative stress explain the burden? Oxidative Medicine and Cellular Longevity, 2017, 1-15.
El Husseini, N., Fonarow, G. C., Smith, E. E., Ju, C., Schwamm, L. H., Hernandez, A. F., Schulte, P. J., Xian, Y., & Goldstein, L. B.. (2017). Renal dysfunction is associated with poststroke discharge disposition and in-hospital mortality: Findings from get with the guidelines-stroke. Stroke, 48, 327-334. https://doi.org/10.1161/STROKEAHA.116.014601
Endemann, D. H., & Schiffrin, E. L. (2004). Endothelial dysfunction. Journal of the American Society of Nephrology, 15, 1983-1992. https://doi.org/10.1097/01.ASN.0000132474.50966.DA
Enomoto, A., Takeda, M., Tojo, A., Sekine, T., Cha, S. H., Khamdang, S., Takayama, F., Aoyama, I., Nakamura, S. & Endou, H. (2002). Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. Journal of the American Society of Nephrology, 13, 1711-1720. https://doi.org/10.1097/01.ASN.0000022017.96399.B2
Eschbach, J. W. (1989). The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney International, 35, 134-148. https://doi.org/10.1038/ki.1989.18
Fabjan, T. H., & Hojs, R. (2014). Stroke and renal dysfunction. European Journal of Internal Medicine, 25, 18-24. https://doi.org/10.1016/j.ejim.2013.08.710
Fehr, T., Ammann, P., Garzoni, D., Korte, W., Fierz, W., Rickli, H., & Wüthrich, R. P. (2004). Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney International, 66, 1206-1211. https://doi.org/10.1111/j.1523-1755.2004.00880.x
Fluss, R., Zguri, L., Rahme, R., & Fulger, I. (2019). Iron-deficiency anemia causes an ischemic stroke in a young man. Cureus, 11. https://doi.org/10.7759/cureus.4218
Flythe, J. E., & Brunelli, S. M. (2014). Blood pressure variability and dialysis: Variability may not always be the spice of life. Journal of the American Society of Nephrology, 25(4), 650-653. https://doi.org/10.1681/ASN.2013111237
Formanowicz, D., Wanic-Kossowska, M., Pawliczak, E., Radom, M., & Formanowicz, P. (2015). Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney disease-systems and clinical approach. Scientific Reports, 5, 18332. https://doi.org/10.1038/srep18332
Fujii, H., Goto, S., & Fukagawa, M. (2018). Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins, 10, 202. https://doi.org/10.3390/toxins10050202
Gajjala, P. R., Fliser, D., Speer, T., Jankowski, V., & Jankowski, J. (2015). Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrology Dialysis Transplantation, 30, 1814-1824. https://doi.org/10.1093/ndt/gfv048
Garcia, D. A., Wallentin, L., Lopes, R. D., Thomas, L., Alexander, J. H., Hylek, E. M., Ansell, J., Hanna, M. Lanas, F., Flaker, G., Commerford, P., Xavier, D., Vinereanu, D., Yang, H., & Granger, C. B. (2013). Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. American Heart Journal, 166, 549-558. https://doi.org/10.1016/j.ahj.2013.05.016
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., Tendera, M., & Tognoni, G. (2018). Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. The Lancet, 392, 1036-1046. https://doi.org/10.1016/S0140-6736(18)31924-X
Ghoshal, S., & Freedman, B. I. (2019). Mechanisms of stroke in patients with chronic kidney disease. American Journal of Nephrology, 50, 229-239. https://doi.org/10.1159/000502446
Giachelli, C. M. (2009). The emerging role of phosphate in vascular calcification. Kidney International, 75, 890-897. https://doi.org/10.1038/ki.2008.644
Gopalratnam, K., Woodson, K. A., Rangunwala, J., Sena, K., & Gupta, M. (2017) A rare case of stroke secondary to iron deficiency anemia in a young female patient. Case reports in medicine, 2017.
Gouroju, S., Rao, P. S., Bitla, A., Vinapamula, K., Manohar, S., & Vishnubhotla, S. (2017). Role of gut-derived uremic toxins on oxidative stress and inflammation in patients with chronic kidney disease. Indian Journal of Nephrology, 27, 359. https://doi.org/10.4103/ijn.IJN_71_17
Group, A.S.C (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine, 379, 1529-1539.
Ha, J. T., Neuen, B. L., Cheng, L. P., Jun, M., Toyama, T., Gallagher, M. P., Jardine, M. J., Sood, M. M., Garg, A. X., & Palmer, S. C. (2019) Benefits and harms of oral anticoagulant therapy in chronic kidney disease. Annals of Internal Medicine, 171(3), 181.
Hassan, A., Hunt, B. J., O’Sullivan, M., Bell, R., D’Souza, R., Jeffery, S., Bamford, J. M., & Markus, H. S. (2004). Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain, 127, 212-219. https://doi.org/10.1093/brain/awh023
Hénaut, L., Grissi, M., Brazier, F., Assem, M., Poirot-Leclercq, S., Lenglet, G., Boudot, C., Avondo, C., Boullier, A., Choukroun, G., Massy, Z. A., Kamel, S., & Chillon, J.-M. (2019). Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease. Scientific Reports, 9, 1-11. https://doi.org/10.1038/s41598-019-42933-0
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., DeLoach, S. S., Pun, P. H., & Ritz, E. (2011). Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 80, 572-586. https://doi.org/10.1038/ki.2011.223
Hörl, W. H. (2007). Iron therapy for renal anemia: How much needed, how much harmful? Pediatric Nephrology, 22, 480-489. https://doi.org/10.1007/s00467-006-0405-y
Horowitz, M., O’donovan, D., Jones, K., Feinle, C., Rayner, C., & Samsom, M. (2002). Gastric emptying in diabetes: Clinical significance and treatment. Diabetic Medicine, 19, 177-194. https://doi.org/10.1046/j.1464-5491.2002.00658.x
Hruska, K. A., Mathew, S., Lund, R., Qiu, P., & Pratt, R. (2008). Hyperphosphatemia of chronic kidney disease. Kidney International, 74, 148-157. https://doi.org/10.1038/ki.2008.130
Huisa, B. N., Caprihan, A., Thompson, J., Prestopnik, J., Qualls, C. R., & Rosenberg, G. A. (2015). Long-term blood-brain barrier permeability changes in Binswanger disease. Stroke, 46, 2413-2418. https://doi.org/10.1161/STROKEAHA.115.009589
Imai, E., Matsuo, S., Makino, H., Watanabe, T., Akizawa, T., Nitta, K., Iimuro, S., Ohashi, Y. & Hishida, A. (2010). Chronic Kidney Disease Japan Cohort study: Baseline characteristics and factors associated with causative diseases and renal function. Clinical and Experimental Nephrology, 14, 558-570. https://doi.org/10.1007/s10157-010-0328-6
Isakova, T., Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., Chen, J., Hamm, L., Gadegbeku, C., Horwitz, E., Townsend, R. R., Anderson, C. A. M., Lash, J. P., Hsu, C.-Y., Leonard, M. B., & Wolf, M. (2011). Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 79, 1370-1378. https://doi.org/10.1038/ki.2011.47
Ito, S., Nagasawa, T., Abe, M., & Mori, T. (2009). Strain vessel hypothesis: A viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertension Research, 32, 115. https://doi.org/10.1038/hr.2008.27
Jing, W., Jabbari, B., & Vaziri, N. D. (2018). Uremia induces upregulation of cerebral tissue oxidative/inflammatory cascade, down-regulation of Nrf2 pathway and disruption of blood brain barrier. American Journal of Translational Research, 10, 2137.
Johnson, L. S., Mattsson, N., Sajadieh, A., Wollmer, P., & Söderholm, M. (2017). Serum potassium is positively associated with stroke and mortality in the large, population-based Malmö Preventive Project cohort. Stroke, 48, 2973-2978. https://doi.org/10.1161/STROKEAHA.117.018148
Kalim, S., Trottier, C. A., Wenger, J. B., Wibecan, J., Ahmed, R., Ankers, E., Karumanchi, S. A., Thadhani, R. & & Berg, A. H. (2016). Longitudinal changes in protein carbamylation and mortality risk after initiation of hemodialysis. Clinical Journal of the American Society of Nephrology, 11, 1809-1816. https://doi.org/10.2215/CJN.02390316
Kalimo, H., Ruchoux, M. M., Viitanen, M., & Kalaria, R. N. (2002). CADASIL: A common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathology, 12, 371-384. https://doi.org/10.1111/j.1750-3639.2002.tb00451.x
Kamouchi, M. (2013). Stroke features and management in patients with chronic kidney disease. In K. Toyoda (Ed.), Brain Stroke and Kidney (Vol. 179, pp. 92-99). Basel, Switzerland: Karger Publishers.
Karim, Z., Attmane-Elakeb, A., & Bichara, M. (2002). Renal handling of NH4+ in relation to the control of acid-base balance by the kidney. Journal of Nephrology, 15, S128-134.
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocrine Reviews, 37, 278-316. https://doi.org/10.1210/er.2015-1137
Kaw, D., & Malhotra, D. (2006). Hematology: Issues in the dialysis patient: Platelet dysfunction and end-stage renal disease. Seminars in Dialysis, 19(4), 317-322.
Kelly, D. M., & Rothwell, P. M. (2019). Prevention and treatment of stroke in patients with chronic kidney disease: An overview of evidence and current guidelines. Kidney International, 97(2), 266-278. https://doi.org/10.1016/j.kint.2019.09.024
Kerr, C. R., & Humphries, K. (2005). Gender-related differences in atrial fibrillation. Journal of the American College of Cardiology.46(7), 1307-1308.
Khan, M. F., Shamael, I., Zaman, Q., Mahmood, A., & Siddiqui, M. (2018). Association of anemia with stroke severity in acute ischemic stroke patients. Cureus, 10(6), e2870. https://doi.org/10.7759/cureus.2870
Khatri, M., Wright, C. B., Nickolas, T. L., Yoshita, M., Paik, M. C., Kranwinkel, G., Sacco, R. L., & DeCarli, C. (2007). Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan Study (NOMAS). Stroke, 38, 3121-3126. https://doi.org/10.1161/STROKEAHA.107.493593
Kielstein, J. T., Donnerstag, F., Gasper, S., Menne, J., Kielstein, A., Martens-Lobenhoffer, J., Scalera, F., Cooke, J. P., Fliser, D., & Bode-Böger, S. M. (2006). ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke, 37, 2024-2029. https://doi.org/10.1161/01.STR.0000231640.32543.11
Kim, H.-Y., Baylis, C., Verlander, J. W., Han, K.-H., Reungjui, S., Handlogten, M. E., & Weiner, I. D. (2007). Effect of reduced renal mass on renal ammonia transporter family, Rh C glycoprotein and Rh B glycoprotein, expression. American Journal of Physiology-Renal Physiology, 293, F1238-F1247. https://doi.org/10.1152/ajprenal.00151.2007
Kim, S. J., Lee, B. H., Kim, Y.-M., Kim, G.-H., & Yoo, H.-W. (2013). Congenital MTHFR deficiency causing early-onset cerebral stroke in a case homozygous for MTHFR thermolabile variant. Metabolic Brain Disease, 28, 519-522. https://doi.org/10.1007/s11011-013-9398-y
Kim, S. H., Shin, D. W., Yun, J. M., Lee, J. E., Lim, J.-S., Cho, B. L., Kwon, H.-M., & Park, J.-H. (2017). Kidney dysfunction and cerebral microbleeds in neurologically healthy adults. PLoS One, 12, e0172210. https://doi.org/10.1371/journal.pone.0172210
Kiu Weber, C. I., Duchateau-Nguyen, G., Solier, C., Schell-Steven, A., Hermosilla, R., Nogoceke, E., & Block, G. (2014). Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. Clinical Kidney Journal, 7, 167-173. https://doi.org/10.1093/ckj/sfu017
Koeth, R. A., Kalantar-Zadeh, K., Wang, Z., Fu, X., Tang, W. W., & Hazen, S. L. (2013). Protein carbamylation predicts mortality in ESRD. Journal of the American Society of Nephrology, 24, 853-861. https://doi.org/10.1681/ASN.2012030254
Kraut, J. A., & Madias, N. E. (2016). Metabolic acidosis of CKD: An update. American Journal of Kidney Diseases, 67(2), 307-317.
Kumral, A., Genc, S., Kutluk, K., & Ozkan, H. (2010). Safety concerns with the clinical use of erythropoietin in acute ischemic stroke. Stroke, 41, e469. https://doi.org/10.1161/STROKEAHA.110.585943
Lau, W. L., Huisa, B. N., & Fisher, M. (2017). The cerebrovascular-chronic kidney disease connection: Perspectives and mechanisms. Translational Stroke Research, 8, 67-76. https://doi.org/10.1007/s12975-016-0499-x
Lau, W. L., Kalantar-Zadeh, K., & Vaziri, N. D. (2015). The gut as a source of inflammation in chronic kidney disease. Nephron, 130, 92-98. https://doi.org/10.1159/000381990
Lau, W. L., Liu, S.-M., Pahlevan, S., Yuan, J., Khazaeli, M., Ni, Z., Chan, J. Y., & Vaziri, N. D. (2015). Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption. Digestive Diseases and Sciences, 60, 1215-1222. https://doi.org/10.1007/s10620-014-3428-4
Lau, W. L., Nunes, A. C., Vasilevko, V., Floriolli, D., Lertpanit, L., Savoj, J., Bangash, M., Yao, Z., Shah, K. & Naqvi, S. (2019). Chronic kidney disease increases cerebral microbleeds in mouse and man. Translational Stroke Research, 11(1), 122-134.
Lehotský, J., Tothová, B., Kovalská, M., Dobrota, D., Beňová, A., Kalenská, D., & Kaplán, P. (2016). Role of homocysteine in the ischemic stroke and development of ischemic tolerance. Frontiers in Neuroscience, 10, 538. https://doi.org/10.3389/fnins.2016.00538
Leong, S., & Sirich, T. (2016). Indoxyl sulfate-Review of toxicity and therapeutic strategies. Toxins, 8, 358. https://doi.org/10.3390/toxins8120358
Lewis, A., & Segal, A. (2010). Hyperlipidemia and primary prevention of stroke: Does risk factor identification and reduction really work? Current Atherosclerosis Reports, 12, 225-229. https://doi.org/10.1007/s11883-010-0117-4
Lisowska-Myjak, B. (2014). Uremic toxins and their effects on multiple organ systems. Nephron Clinical Practice, 128, 303-311. https://doi.org/10.1159/000369817
Locatelli, F., Cannata-Andía, J. B., Drüeke, T. B., Hörl, W. H., Fouque, D., Heimburger, O., & Ritz, E. (2002). Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrology Dialysis Transplantation, 17, 723-731. https://doi.org/10.1093/ndt/17.5.723
Majid, A., Delanty, N., & Kantor, J. (2001). Antiplatelet agents for secondary prevention of ischemic stroke. Annals of Pharmacotherapy, 35(10), 1241-1247.
Major, R. W., Oozeerally, I., Dawson, S., Riddleston, H., Gray, L. J., & Brunskill, N. J. (2016). Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis, 251, 177-182. https://doi.org/10.1016/j.atherosclerosis.2016.06.013
Margetic, S. (2012). Inflammation and hemostasis. Biochemia Medica, 22, 49-62. https://doi.org/10.11613/BM.2012.006
Masson, P., Webster, A. C., Hong, M., Turner, R., Lindley, R. I., & Craig, J. C. (2015). Chronic kidney disease and the risk of stroke: A systematic review and meta-analysis. Nephrology Dialysis Transplantation, 30, 1162-1169. https://doi.org/10.1093/ndt/gfv009
Mazumder, M. K., Paul, R., Bhattacharya, P., & Borah, A. (2019). Neurological sequel of chronic kidney disease: From diminished acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Scientific Reports, 9, 1-22. https://doi.org/10.1038/s41598-018-37935-3
McCarty, M. F. (2004). Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-An explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Medical Hypotheses, 63, 699-708. https://doi.org/10.1016/j.mehy.2002.11.008
McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C. Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., … Murray, A. M. (2018). Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine, 379, 1519-1528. https://doi.org/10.1056/NEJMoa1803955
Mead, G. E., Shingler, H., Farrell, A., & O'Neill, P. A. & Mccollum, C. N. (1998). Carotid disease in acute stroke. Age and Ageing, 27, 677-682. https://doi.org/10.1093/ageing/27.6.677
Members, A. T. F., Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., … Verheugt, F. W. A. (2012). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. European Heart Journal, 33, 2719-2747. https://doi.org/10.1093/eurheartj/ehs253
Mercadal, L., Metzger, M., Casadevall, N., Haymann, J. P., Karras, A., Boffa, J.-J., Flamant, M., Vrtovsnik, F., Stengel, B., & Froissart, M. (2012). Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clinical Journal of the American Society of Nephrology, 7, 35-42. https://doi.org/10.2215/CJN.04690511
Meyer, J. S., Rogers, R. L., & Mortel, K. F. (1984). Progressive cerebral ischemia antedates cerebrovascular symptoms by two years. Annals of Neurology, 16, 314-320. https://doi.org/10.1002/ana.410160307
Minnerup, J., Heidrich, J., Rogalewski, A., Schäbitz, W.-R.-D. & Wellmann, J. (2009). The efficacy of erythropoietin and its analogues in animal stroke models: A meta-analysis. Stroke, 40, 3113-3120. https://doi.org/10.1161/STROKEAHA.109.555789
Miyazaki, T., Ise, M., Hirata, M., Endo, K., Ito, Y., Seo, H., & Niwa, T. (1997). Indoxyl sulfate stimulates renal synthesis of transforming growth factor-β1 and progression of renal failure. Kidney International Supplement, 63, S211-S214.
Müting, D. (1965). Studies on the pathogenesis of uremia comparatie determinaions of glucuronic acid, indican, free and bound phenols in the serum, cerebrospinal fluid, and urine of renal diseases with and without uremia. Clinica Chimica Acta, 12, 551-554. https://doi.org/10.1016/0009-8981(65)90171-3
Naganuma, T., Takemoto, Y., Shoji, T., Ishimura, E., Okamura, M., & Nakatani, T. (2015). Cerebral microbleeds predict intracerebral hemorrhage in hemodialysis patients. Stroke, 46, 2107-2112. https://doi.org/10.1161/STROKEAHA.115.009324
Naqvi, I., Hitomi, E., & Leigh, R. (2019). Sustained opening of the blood-brain barrier with progressive accumulation of white matter hyperintensities following ischemic stroke. Brain Sciences, 9, 16. https://doi.org/10.3390/brainsci9010016
Nath, K. A., Hostetter, M. K., & Hostetter, T. H. (1991). Increased ammoniagenesis as a determinant of progressive renal injury. American Journal of Kidney Diseases, 17, 654-657. https://doi.org/10.1016/S0272-6386(12)80344-1
Neto, P. A., Gomes, H. V., & Campos, M. (2013). Management of hyperglycemia in patients with chronic kidney disease. Journal of Nephrology, 26, 629-635. https://doi.org/10.5301/jn.5000248
Ninomiya, T. (2013). Risk of stroke in kidney disease. Brain Stroke and Kidney (pp. 58-66). Basel, Switzerland: Karger Publishers.
Nongnuch, A., Panorchan, K., & Davenport, A. (2014). Brain-kidney crosstalk. Critical Care, 18, 225. https://doi.org/10.1186/cc13907
O’Rourke, M. F., & Safar, M. E. (2005). Relationship between aortic stiffening and microvascular disease in brain and kidney: Cause and logic of therapy. Hypertension, 46, 200-204. https://doi.org/10.1161/01.HYP.0000168052.00426.65
Ocak, G., Verduijn, M., Vossen, C. Y., Lijfering, W. M., Dekker, F. W., Rosendaal, F. R., Gansevoort, R. T., & Mahmoodi, B. K. (2010). Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 8, 2428-2435.
Ok, E., Basnakian, A. G., Apostolov, E. O., Barri, Y. M., & Shah, S. V. (2005). Carbamylated low-density lipoprotein induces death ofendothelial cells: A link to atherosclerosis in patients with kidney disease. Kidney International, 68, 173-178. https://doi.org/10.1111/j.1523-1755.2005.00391.x
Olesen, J. B., Lip, G. Y., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H. & et al (2012). Stroke and bleeding in atrial fibrillation with chronic kidney disease. New England Journal of Medicine, 367, 625-635. https://doi.org/10.1056/NEJMoa1105594
Oshima, N., Onimaru, H., Matsubara, H., Uchida, T., Watanabe, A., Takechi, H., Nishida, Y., & Kumagai, H. (2015). Uric acid, indoxyl sulfate, and methylguanidine activate bulbospinal neurons in the RVLM via their specific transporters and by producing oxidative stress. Neuroscience, 304, 133-145. https://doi.org/10.1016/j.neuroscience.2015.07.055
Ovbiagele, B., Wing, J. J., Menon, R. S., Burgess, R. E., Gibbons, M. C., Sobotka, I., German, L., Shara, N. M., Fernandez, S., Jayam-Trouth, A., Edwards, D. F., & Kidwell, C. S. (2013). Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke, 44, 2409-2413. https://doi.org/10.1161/STROKEAHA.113.001958
Palmer, S. C., Di Micco, L., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Jardine, M. J., Webster, A. C. Zoungas, S., & Strippoli, G. F. (2013). Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews, 30(4), CD008834.
Palumbo, P., Elveback, L., & Whisnant, J. (1978). Neurologic complications of diabetes mellitus: Transient ischemic attack, stroke, and peripheral neuropathy. Advances in Neurology, 19, 593.
Pantoni, L. (2010). Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. The Lancet Neurology, 9, 689-701. https://doi.org/10.1016/S1474-4422(10)70104-6
Parsons, M. W., Barber, P. A., Desmond, P. M., Baird, T. A., Darby, D. G., Byrnes, G., Tress, B. M., & Davis, S. M. (2002). Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Annals of Neurology, 52, 20-28. https://doi.org/10.1002/ana.10241
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A., & Califf, R. M. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883-891. https://doi.org/10.1056/NEJMoa1009638
Peng, X., Haldar, S., Deshpande, S., Irani, K., & Kass, D. A. (2003). Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension, 41, 378-381. https://doi.org/10.1161/01.HYP.0000049624.99844.3D
Petras, M., Tatarkova, Z., Kovalska, M., Mokra, D., Dobrota, D., Lehotsky, J., & Drgova, A. (2014). Hyperhomocysteinemia as a risk factor for the neuronal system disorders. Physiology and Pharmacology, 65, 15-23.
Pietrement, C., Gorisse, L., Jaisson, S., & Gillery, P. (2013). Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. PLoS One, 8, e82506. https://doi.org/10.1371/journal.pone.0082506
Poddar, R., & Paul, S. (2013). Novel crosstalk between ERK MAPK and p38 MAPK leads to homocysteine-NMDA receptor-mediated neuronal cell death. J Journal of Neurochemistry, 124, 558-570. https://doi.org/10.1111/jnc.12102
Power, A., Epstein, D., Cohen, D., Bathula, R., Devine, J., Kar, A., Taube, D., Duncan, N. & Ames, D. (2013). Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Cerebrovascular Diseases, 35, 45-52. https://doi.org/10.1159/000345071
Prado, R., Ginsberg, M. D., Dietrich, W. D., Watson, B. D., & Busto, R. (1988). Hyperglycemia increases infarct size in collaterally perfused but not end-arterial vascular territories. Journal of Cerebral Blood Flow & Metabolism, 8, 186-192. https://doi.org/10.1038/jcbfm.1988.48
Provatopoulou, S., & Ziroyiannis, P. (2011). Clinical use of erythropoietin in chronic kidney disease: Outcomes and future prospects. Hippokratia, 15, 109.
Qamar, A., & Bhatt, D. L. (2016). Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circulation, 133, 1512-1515. https://doi.org/10.1161/CIRCULATIONAHA.115.018549
Rehncrona, S. (1985). Brain acidosis. Annals of Emergency Medicine, 14, 770-776. https://doi.org/10.1016/S0196-0644(85)80055-X
Rose, B. D. (1981). Pathophysiology of renal disease. New York, NY: McGraw-Hill Professional.
Rossi, M., Campbell, K. L., Johnson, D. W., Stanton, T., Vesey, D. A., Coombes, J. S., Weston, K. S., Hawley, C. M., McWhinney, B. C., Ungerer, J. P. J., & Isbel, N. (2014). Protein-bound uremic toxins, inflammation and oxidative stress: A cross-sectional study in stage 3-4 chronic kidney disease. Archives of Medical Research, 45, 309-317. https://doi.org/10.1016/j.arcmed.2014.04.002
Sadamoto, Y., Igase, K., Sakanaka, M., Sato, K., Otsuka, H., Sakaki, S., Masuda, S., & Sasaki, R. (1998). Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochemical and Biophysical Research Communications, 253, 26-32. https://doi.org/10.1006/bbrc.1998.9748
Saleem, S., Yousuf, I., Gul, A., Gupta, S., & Verma, S. (2014). Hyponatremia in stroke. Annals of Indian Academy of Neurology, 17, 55-57. https://doi.org/10.4103/0972-2327.128554
Sandsmark, D. K., Messé, S. R., Zhang, X., Roy, J., Nessel, L., Lee Hamm, L., He, J., Horwitz, E. J. et al (2015). Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: Chronic renal insufficiency cohort study. Stroke, 46, 2075-2080. https://doi.org/10.1161/STROKEAHA.115.009861
Sarmah, D., Kaur, H., Saraf, J., Pravalika, K., Goswami, A., Kalia, K., Borah, A., Wang, X. et al (2018). Getting closer to an effective intervention of ischemic stroke: The big promise of stem cell. Translational Stroke Research, 9, 356-374. https://doi.org/10.1007/s12975-017-0580-0
Sarmah, D., Kaur, H., Saraf, J., Vats, K., Pravalika, K., Wanve, M., Kalia, K., Borah, A., Kumar, A., Wang, X., Yavagal, D. R., Dave, K. R., & Bhattacharya, P. (2019). Mitochondrial dysfunction in stroke: Implications of stem cell therapy. Translational Stroke Research, 10, 121-136. https://doi.org/10.1007/s12975-018-0642-y
Schuchardt, M., Tölle, M., & van der Giet, M. (2015). High-density lipoprotein: Structural and functional changes under uremic conditions and the therapeutic consequences. In A. Eckardstein & D. Kardassis (Eds.), High density lipoproteins (pp. 423-453). Cham, Switzerland: Springer.
Segarra, G., Medina, P., Ballester, R., Lluch, P., Aldasoro, M., Vila, J., Lluch, S., & Pelligrino, D. (1999). Effects of some guanidino compounds on human cerebral arteries. Stroke, 30, 2206-2209. https://doi.org/10.1161/01.STR.30.10.2206
Seifter, J. L., & Samuels, M. A. (2011) Uremic encephalopathy and other brain disorders associated with renal failure. Vol. 31, Seminars in neurology. © Thieme Medical Publishers, City. pp. 139-143.
Seshadri, S. (2006). Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease? Journal of Alzheimer's Disease, 9, 393-398. https://doi.org/10.3233/JAD-2006-9404
Sharma, M., Zhou, Z., Miura, H., Papapetropoulos, A., McCarthy, E. T., Sharma, R., Savin, V. J., & Lianos, E. A. (2009). ADMA injures the glomerular filtration barrier: Role of nitric oxide and superoxide. American Journal of Physiology-Renal Physiology, 296, F1386-F1395. https://doi.org/10.1152/ajprenal.90369.2008
Shima, H., Ishimura, E., Naganuma, T., Yamazaki, T., Kobayashi, I., Shidara, K., Mori, K., Takemoto, Y., Shoji, T., Inaba, M., Okamura, M., Nakatani, T., & Nishizawa, Y. (2009). Cerebral microbleeds in predialysis patients with chronic kidney disease. Nephrology Dialysis Transplantation, 25, 1554-1559. https://doi.org/10.1093/ndt/gfp694
Shin, Y.-K., & Cho, S.-R. (2016). Exploring erythropoietin and G-CSF combination therapy in chronic stroke patients. International Journal of Molecular Sciences, 17, 463. https://doi.org/10.3390/ijms17040463
Shroff, R. C., McNair, R., Skepper, J. N., Figg, N., Schurgers, L. J., Deanfield, J., Rees, L., & Shanahan, C. M. (2010). Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. Journal of the American Society of Nephrology, 21, 103-112. https://doi.org/10.1681/ASN.2009060640
Singh, A. K., & Williams, G. H. (2009). Textbook of nephro-endocrinology. USA: Academic Press.
Sirén, A.-L., Knerlich, F., Poser, W., Gleiter, C. H., Brück, W., & Ehrenreich, H. (2001). Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathologica, 101, 271-276. https://doi.org/10.1007/s004010000297
Slatopolsky, E., Gradowska, L., Kashemsant, C., Keltner, R., Manley, C., & Bricker, N. (1966). The control of phosphate excretion in uremia. Journal of Clinical Investigation, 45, 672-677. https://doi.org/10.1172/JCI105382
Streck, E. L., Delwing, D., Tagliari, B., Matté, C., Wannmacher, C. M., Wajner, M., & Wyse, A. T. (2003). Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochemistry International, 43, 597-602. https://doi.org/10.1016/S0197-0186(02)00230-9
Streck, E. L., Zugno, A. I., Tagliari, B., Wannmacher, C. M., Wajner, M., & Wyse, A. T. (2002). Inhibition of Na+, K+-ATPase activity by the metabolites accumulating in homocystinuria. Metabolic Brain Disease, 17, 83-91.
Sutherland, L. J., Diprose, W. K., Wang, M. T., & Barber, P. A. (2020). Chronic kidney disease and outcome following endovascular thrombectomy for acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 29, 104665. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104665
Tamura, M. K., Pajewski, N. M., Bryan, R. N., Weiner, D. E., Diamond, M., Van Buren, P., Taylor, A., Beddhu, S., Rosendorff, C., Jahanian, H., & Zaharchuk, G. (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86, 1208-1216. https://doi.org/10.1212/WNL.0000000000002527
Tang, W., Liang, H., Chen, Y., Ahuja, A., Chu, W. C., Mok, V., Ungvari, G. S., & Wong, K. (2013). White matter hyperintensities and quality of life in acute lacunar stroke. Neurological Sciences, 34, 1347-1353. https://doi.org/10.1007/s10072-012-1267-7
Tang, W. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S. & Hazen, S. L. (2015). Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circulation Research, 116, 448-455.
Tanner, R. M., Shimbo, D., Dreisbach, A. W., Carson, A. P., Fox, E. R., & Muntner, P. (2015). Association between 24-hour blood pressure variability and chronic kidney disease: A cross-sectional analysis of African Americans participating in the Jackson heart study. BMC Nephrology, 16, 84. https://doi.org/10.1186/s12882-015-0085-6
Tannock, L. (2018). Dyslipidemia in chronic kidney disease Endotext [Internet]. MDText. com, Inc..
Tonelli, M., Karumanchi, S. A., & Thadhani, R. (2016). Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation, 133, 518-536. https://doi.org/10.1161/CIRCULATIONAHA.115.018713
Tonelli, M., Sacks, F., Pfeffer, M., Gao, Z., & Curhan, G. (2005). Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation, 112, 2627-2633. https://doi.org/10.1161/CIRCULATIONAHA.105.553198
Toyoda, K. (2013). Cerebrorenal interaction and stroke. In K. Toyoda (Ed.), Brain stroke and kidney (Vol. 179, pp. 1-6). Basel, Switzerland: Karger Publishers.
Tsagalis, G., Akrivos, T., Alevizaki, M., Manios, E., Stamatellopoulos, K., Laggouranis, A., & Vemmos, K. N. (2008). Renal dysfunction in acute stroke: An independent predictor of long-term all combined vascular events and overall mortality. Nephrology Dialysis Transplantation, 24, 194-200. https://doi.org/10.1093/ndt/gfn471
Tsai, T.-H., Lu, C.-H., Wallace, C. G., Chang, W.-N., Chen, S.-F., Huang, C.-R., Tsai, N.-W., Lan, M.-Y., Sung, P.-H., Liu, C.-F., & Yip, H.-K. (2015). Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: A randomized, prospective, placebo-controlled clinical trial. Critical Care, 19, 49. https://doi.org/10.1186/s13054-015-0761-8
Tsai, Y.-H., Lee, M., Lin, L.-C., Chang, S.-W., Weng, H.-H., Yang, J.-T., Huang, Y.-C., & Lee, M.-H. (2018). Association of chronic kidney disease with small vessel disease in patients with hypertensive intracerebral hemorrhage. Frontiers in Neurology, 9, 284. https://doi.org/10.3389/fneur.2018.00284
Umemura, T., Kawamura, T., Sakakibara, T., Mashita, S., Hotta, N., & Sobue, G. (2012). Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults. American Journal of Hypertension, 25, 430-436. https://doi.org/10.1038/ajh.2011.254
Unger, T., Badoer, E., Ganten, D., Lang, R., & Rettig, R. (1988). Brain angiotensin: Pathways and pharmacology. Circulation, 77, I40-54.
Van der Donckt, C., Van Herck, J. L., Schrijvers, D. M., Vanhoutte, G., Verhoye, M., Blockx, I., Van Der Linden, A., Bauters, D. Lijnen, H. R., Sluimer, J. C., Roth, L., Van Hove, C. E., Fransen, P., Knaapen, M. W., Hervent, A.-S., De Keulenaer, G. R. Y. (2014). Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. European Heart Journal, 36, 1049-1058. https://doi.org/10.1093/eurheartj/ehu041
Vaziri, N. D., Deng, G., & Liang, K. (1999). Hepatic HDL receptor, SR-B1 and Apo AI expression in chronic renal failure. Nephrology, Dialysis, Transplantation, 14, 1462-1466.
Vaziri, N. D., Yuan, J., & Norris, K. (2013). Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. American Journal of Nephrology, 37, 1-6. https://doi.org/10.1159/000345969
Vaziri, N. D., Yuan, J., Rahimi, A., Ni, Z., Said, H., & Subramanian, V. S. (2011). Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. Nephrology Dialysis Transplantation, 27, 2686-2693. https://doi.org/10.1093/ndt/gfr624
Velasquez, M. T., Ramezani, A., & Raj, D. S. (2015). Urea and protein carbamylation in ESRD: Surrogate markers or partners in crime? Kidney International, 87, 1092-1094. https://doi.org/10.1038/ki.2015.78
Verbrugge, F. H., Tang, W. W., & Hazen, S. L. (2015). Protein carbamylation and cardiovascular disease. Kidney International, 88, 474-478. https://doi.org/10.1038/ki.2015.166
Viggiano, D., Wagner, C. A., Blankestijn, P. J., Bruchfeld, A., Fliser, D., Fouque, D., Frische, S., Gesualdo, L., Gutiérrez, E., Goumenos, D., Hoorn, E. J., Eckardt, K.-U., Knauß, S., König, M., Malyszko, J., Massy, Z., Nitsch, D., Pesce, F., Rychlík, I., … Capasso, G. (2019). Mild cognitive impairment and kidney disease: Clinical aspects. Nephrology Dialysis Transplantation, 35(1), 10-17. https://doi.org/10.1093/ndt/gfz051
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M. et al (2003). Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Journal of Experimental Medicine, 198, 971-975. https://doi.org/10.1084/jem.20021067
Wada, M., Nagasawa, H., Iseki, C., Takahashi, Y., Sato, H., Arawaka, S., Kawanami, T., Kurita, K., Daimon, M., & Kato, T. (2008). Cerebral small vessel disease and chronic kidney disease (CKD): Results of a cross-sectional study in community-based Japanese elderly. Journal of the Neurological Sciences, 272, 36-42. https://doi.org/10.1016/j.jns.2008.04.029
Wardlaw, J. M., Valdés Hernández, M. C., & Muñoz-Maniega, S. (2015). What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. Journal of the American Heart Association, 4, e001140.
Weiner, D. E., Bartolomei, K., Scott, T., Price, L. L., Griffith, J. L., Rosenberg, I., Levey, A. S., Folstein, M. F. & et al (2009). Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. American Journal of Kidney Diseases, 53, 438-447. https://doi.org/10.1053/j.ajkd.2008.08.022
Wilson, D., Ambler, G., Lee, K.-J., Lim, J.-S., Shiozawa, M., Koga, M., Li, L., Lovelock, C., Chabriat, H., Hennerici, M., Wong, Y. K., Mak, H. K. F., Prats-Sánchez, L., Martínez-Domeño, A., Inamura, S., Yoshifuji, K., Arsava, E. M., Horstmann, S., Purrucker, J. … Mitchell, J. (2019). Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: A pooled analysis of individual patient data from cohort studies. The Lancet Neurology, 18, 653-665. https://doi.org/10.1016/S1474-4422(19)30197-8
Yamada, S., Tsuruya, K., Taniguchi, M., Tokumoto, M., Fujisaki, K., Hirakata, H., Fujimi, S., & Kitazono, T. (2016). Association between serum phosphate levels and stroke risk in patients undergoing hemodialysis: The Q-Cohort Study. Stroke, 47, 2189-2196. https://doi.org/10.1161/STROKEAHA.116.013195
Yip, H.-K., Tsai, T.-H., Lin, H.-S., Chen, S.-F., Sun, C.-K., Leu, S., Yuen, C.-M., Tan, T.-Y. et al (2011). Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Critical Care, 15, R40. https://doi.org/10.1186/cc10002
Yokota, C., Minematsu, K., Ito, A., Toyoda, K., Nagasawa, H., & Yamaguchi, T. (2009). Albuminuria, but not metabolic syndrome, is a significant predictor of stroke recurrence in ischemic stroke. Journal of the Neurological Sciences, 277, 50-53. https://doi.org/10.1016/j.jns.2008.10.002
Zhang, Y.-Z., Qie, J.-Y., & Zhang, Q.-H. (2015). Incidence and mortality prognosis of dysnatremias in neurologic critically ill patients. European Neurology, 73, 29-36. https://doi.org/10.1159/000368353
Zhao, Y., Huang, G., Chen, S., Gou, Y., Dong, Z., & Zhang, X. (2016). Homocysteine aggravates cortical neural cell injury through neuronal autophagy overactivation following rat cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 17, 1196. https://doi.org/10.3390/ijms17081196
Zhao, G., Lin, F., Wang, Z., Shao, X., Gong, Y., Zhang, S., … Wang, L. (2019). Dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke. European Neurology, 82(4-6), 93-98.
Zuo, Y., Yancey, P., Castro, I., Khan, W., Motojima, M., Ichikawa, I., Fogo, A. B., Linton, M. F., Fazio, S., & Kon, V. (2009). Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 1277-1282. https://doi.org/10.1161/ATVBAHA.109.188995